Earnings summaries and quarterly performance for RSLS.
Executive leadership at RSLS.
Board of directors at RSLS.
Research analysts covering RSLS.
Recent press releases and 8-K filings for RSLS.
Vyome Holdings, Inc. Completes Merger, Reports Q2 2025 Financials, and Announces Reverse Stock Split
RSLS
M&A
Earnings
Debt Issuance
- Vyome Holdings, Inc. (formerly ReShape Lifesciences Inc.) completed its merger with Vyome Therapeutics, Inc. on August 15, 2025, with Vyome Therapeutics, Inc. surviving as a subsidiary, and the combined company changing its name to Vyome Holdings, Inc..
- For the six months ended June 30, 2025, the company reported revenue of $248,536, an increase from $110,990 for the same period in 2024, while the net loss increased to $(602,732) from $(593,132).
- The company secured $7.3 million in concurrent financing, with $6.9 million received in August 2025, and expects to use approximately $5.0 million for operating expenses and capital expenditures for up to fifteen months post-merger.
- The Board of Directors approved a 1-for-5,000 reverse stock split in August 2025.
Sep 2, 2025, 12:04 PM
Quarterly earnings call transcripts for RSLS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more